Skip to main content
main-content

Cardiovascular disorders


Browse the latest news, expert commentary, and educational content on cardiovascular disorders.


Highlights

01-21-2021 | SGLT2 inhibitors | News

Meta-analysis underscores individual risk profile impact on GLP-1, SGLT2 benefits

A network meta-analysis highlights the impact of individual risk profiles on the absolute benefits offered by GLP-1 receptor agonists and SGLT2 inhibitors for people with type 2 diabetes.

01-20-2021 | Empagliflozin | News

EMPA-TROPISM: Empagliflozin improves LV remodeling in patients with heart failure

Adding the SGLT2 inhibitor empagliflozin to standard treatment significantly improves left ventricular remodeling among patients with heart failure and reduced ejection fraction but without diabetes, shows a randomized controlled trial.

01-05-2021 | Heart failure | News

Support for fluid reduction mechanism underlying SGLT2 inhibitor cardiorenal benefits

The SGLT2 inhibitor empagliflozin reduces estimated extracellular volume and plasma volume in patients who have heart failure with reduced ejection fraction, shows a randomized trial.

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

More on cardiovascular disorders

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits